PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23122726-8 2012 Further, metformin reduced TLR-dependent inflammatory cytokines as indexed by reduced myocardial levels of TNFalpha (maximum 68%; P<0.001) and IL6 (maximum 84%; P<0.001) as well as by reduced myocardial MPO activity (25%; P<0.01). Metformin 9-18 interleukin 6 Rattus norvegicus 146-149 34375188-11 2022 RESULTS: Astaxanthin and metformin have anti-obesity and antioxidant actions and significantly decreased the weight of the body, glucose, insulin, triglycerides, total cholesterol, triglycerides and leptin, as well as plasma calprotectin & IL-6 and increased HDL-C and adiponectin. Metformin 25-34 interleukin 6 Rattus norvegicus 240-244 21457706-11 2011 At the transcriptional levels, metformin treatment caused significant restoration in diabetic nephropathy-induced oxidative stress mRNA levels, particularly GSTalpha, NQO1, and CAT genes, whereas inhibited TNF-alpha and IL-6 pro-inflammatory genes. Metformin 31-40 interleukin 6 Rattus norvegicus 220-224 33232283-8 2020 Furthermore, metformin activated phosphorylated AMPK, decreased pro-inflammatory cytokines, TNF-alpha, IL-6 and IL-1beta, and decreased NLRP3 inflammasome activation. Metformin 13-22 interleukin 6 Rattus norvegicus 103-107 34280460-0 2021 Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1beta, IL-6, IL-10 and TNF-alpha. Metformin 0-9 interleukin 6 Rattus norvegicus 115-119 16322356-8 2006 Increases in biomarkers of inflammation (e.g., interleukin 6, interferon gamma, and neutrophil number) were also blunted by metformin treatment. Metformin 124-133 interleukin 6 Rattus norvegicus 47-60 33217690-11 2021 However, metformin co-administration significantly decreased the levels of TNF-alpha, IL-6 and IL-1beta while increased the level of IL-10 in epididymal white adipose tissue compared to olanzapine-treated rats. Metformin 9-18 interleukin 6 Rattus norvegicus 86-90 34041677-10 2021 Vildagliptin and metformin not only restored the above but also decreased the expression of IL-6, NFkappaB, SOCS-3 along with lipid accumulation. Metformin 17-26 interleukin 6 Rattus norvegicus 92-96 33666871-9 2021 Compared with the model group, IL-6 and visfatin levels were significantly decreased in the acupuncture and metformin groups (P<0.05). Metformin 108-117 interleukin 6 Rattus norvegicus 31-35 33781829-10 2021 After activation of AMPK by metformin, expressions of p-AMPKalpha, SIRT1 were significantly raised, while expressions of Beclin-1, LC3 II/I, p62, TNF-alpha, IL-6 were reduced, and the number of autophagosome was decreased significantly in caerulein-stimulated AR42J cells. Metformin 28-37 interleukin 6 Rattus norvegicus 157-161 32550202-10 2020 Results: Treatment with metformin/donepezil combination significantly reduced the activities of AchE, BchE as well as levels of malondialdehyde, TNF-alpha and IL-6, while the activities of SOD, GPx and catalase were significantly increased in the brain. Metformin 24-33 interleukin 6 Rattus norvegicus 159-163 32270948-9 2020 In addition, metformin significantly attenuated IL-6, IL-1beta, and TNF-alpha production and increased the expression of active caspase-3 and Bax in the liver (p<0.05). Metformin 13-22 interleukin 6 Rattus norvegicus 48-52 32877649-9 2020 Marjoram alone or in combination with metformin prominently decreased the IL-6 level and improved the levels of ovarian SOD and GPx enzymes (P-value<0.05). Metformin 38-47 interleukin 6 Rattus norvegicus 74-78 31781324-4 2019 Results: Compared with the PQ group, the MET treatment group showed significantly (1) reduced lung wet/dry ratio (W/D: 4.67 +- 0.31 vs. 5.45 +- 0.40, P < 0.001), (2) reduced pathological changes in lung tissue, (3) decreased MDA levels (nmol/mg prot: 2.70 +- 0.19 vs. 3.08 +- 0.15, P < 0.001) and increased SOD and GSH-Px activities (U/mg prot: 76.17 +- 5.22 vs. 45.23 +- 6.58, 30.40 +- 2.84 vs. 21.00 +- 3.20; all P < 0.001) in lung tissue homogenate, (4) reduced levels of IL-1beta, IL-6, and TNF-alpha in lung tissue homogenates (pg/mL: 47.87 +- 5.06 vs. 66.77 +- 6.55; 93.03 +- 7.41 vs. 107.39 +- 9.81; 75.73 +- 6.08 vs. 89.12 +- 8.94; all P < 0.001), (5) increased activity of RLE-6TN cells (%: 0.69 +- 0.09, 0.76 +- 0.06, and 0.58 +- 0.03 vs. 0.50 +- 0.05; all P < 0.05), (6) decreased protein levels of phospho-NF-kappaBp65 in lung homogenates and RLE-6TN cells (p-NF-kappaB/NF-kappaB: 0.47 +- 0.09 vs. 0.81 +- 0.13; 0.26 +- 0.07 vs. 0.79 +- 0.13; all P < 0.01), and (7) upregulated protein expression of phospho-AMPK in lung homogenates and RLE-6TN cells (p-AMPK/AMPK: 0.88 +- 0.05 vs. 0.36 +- 0.12; 0.93 +- 0.03 vs. 0.56 +- 0.15; all P < 0.01). Metformin 41-44 interleukin 6 Rattus norvegicus 494-498 32404018-7 2020 In addition, metformin significantly (p < .05) reduced hyperglycemia, glycated hemoglobin (HbA1 c), malondialdehyde (MDA), high sensitivity C-reactive protein (hs-CRP), and interleukin-6 blood levels induced by diabetes. Metformin 13-22 interleukin 6 Rattus norvegicus 173-186 33184242-11 2020 We found Metformin pre-treatment attenuated human and rat cardiomyocytes apoptosis, HMGB1, TNFalpha and IL-6 release and ROS production that were induced by high-glucose stimulation, and these effects of metformin could be blocked by okadaic acid treatment. Metformin 9-18 interleukin 6 Rattus norvegicus 104-108 33184242-11 2020 We found Metformin pre-treatment attenuated human and rat cardiomyocytes apoptosis, HMGB1, TNFalpha and IL-6 release and ROS production that were induced by high-glucose stimulation, and these effects of metformin could be blocked by okadaic acid treatment. Metformin 204-213 interleukin 6 Rattus norvegicus 104-108 30445633-8 2019 Immunohistochemistry and western blotting showed that without interfering the metabolism of NMBzA, metformin inhibited the inflammation of esophagi via reducing the expressions of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and interleukin-6 (IL-6). Metformin 99-108 interleukin 6 Rattus norvegicus 249-262 31563650-9 2019 Meanwhile in rats with NAFLD: i) metformin inhibited hepatic total cholesterol and TGF-beta, increased diarrhea frequency, and slightly decreased liver steatosis, and fibrosis; ii) 4-hydroxychalcone decreased IL-6, TNF-alpha and TGF-beta, increased IL-10, and markedly decreased liver steatosis and fibrosis; and iii) co-treatment markedly decreased food intake, total caloric intake, and body weight, increased diarrhea; increased IL-10, showing and intermediate effect on decrease TNF-alpha, TGF-beta, liver steatosis and fibrosis. Metformin 33-42 interleukin 6 Rattus norvegicus 209-213 31132357-5 2019 The results suggested metformin decreased the inflammatory response by reducing the expression of proinflammatory cytokines (TNF-alpha, IL-1beta and IL-6), myeloperoxidase activity, and malondialdehyde levels. Metformin 22-31 interleukin 6 Rattus norvegicus 149-153 30445633-8 2019 Immunohistochemistry and western blotting showed that without interfering the metabolism of NMBzA, metformin inhibited the inflammation of esophagi via reducing the expressions of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and interleukin-6 (IL-6). Metformin 99-108 interleukin 6 Rattus norvegicus 264-268 31142603-7 2019 Our data show that metformin increased IL-10 and IDO expression in Ad-hMSCs and decreased high-mobility group box 1 protein, IL-1beta, and IL-6 expression. Metformin 19-28 interleukin 6 Rattus norvegicus 139-143 31210335-11 2019 GW9662 treatment resulted in elevated expressions of MCP-1, TNF-alpha and IL-6, which were reversed by metformin treatment. Metformin 103-112 interleukin 6 Rattus norvegicus 74-78 31210335-12 2019 CONCLUSIONS: Metformin can effectively inhibit the mRNA and protein expressions of IL-6, MCP-1, and TNF-alpha in LPS-induced VSMCs. Metformin 13-22 interleukin 6 Rattus norvegicus 83-87 28664399-12 2017 Furthermore, metformin downregulated the levels of apoptotic factors (p-JNK3, p-c-Jun and cleaved caspase-3) as well as pro-inflammatory cytokines (IL-1beta, IL-4 and IL-6 and TNF-alpha). Metformin 13-22 interleukin 6 Rattus norvegicus 167-171 27897089-10 2017 Metformin supplementation downregulated the d-galactose induced expressions of sirtuin-2, IL-6, and TNF-alpha expression, whereas upregulated the Beclin-1 expression. Metformin 0-9 interleukin 6 Rattus norvegicus 90-94 23659985-14 2013 Similarly, metformin treatment of a placental cell line suppressed TNF-alpha-induced IL-6 levels by NFkappaB inhibitor. Metformin 11-20 interleukin 6 Rattus norvegicus 85-89 29698747-10 2018 Moreover, metformin administration inhibited microglial activation and decreased the production of pro-inflammatory cytokines including TNF-alpha, IL-1beta and IL-6. Metformin 10-19 interleukin 6 Rattus norvegicus 160-164 28933769-7 2017 Interestingly, RA-3 displayed a slightly more enhanced effect than metformin in reducing elevated IL-6 levels and in improving beta cell ultrastructure. Metformin 67-76 interleukin 6 Rattus norvegicus 98-102